4 Nov 2015 07:00
4 November 2015
Port Erin Biopharma Investments Limited
(the "Company")
Â
Net Asset Value calculation to 30 September 2015
Â
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2015 was 10.04 pence per share, including un-invested cash of £67,542. The portfolio is valued under IFRS at bid price.
Net Assets stand at £2.3 million including Investments of £2.26 million. This quarter's NAV represents a decrease of 12.5% from the previous valuation of 11.47 pence per share, which included un-invested cash of £255,564. On this basis, no additional management fee is due to Shellbay Investments Limited.
The reported NAV to 30 September 2015 suffered due to some short-term share price fluctuations across the portfolio during the quarter. The company's three principal investments continue to show significant growth potential for the remainder of 2015 and beyond".
Â
Unaudited to 30 September 2015 £ | ||
Fixed Assets | ||
Investments | 2,268,245 | |
Current Assets | ||
Sundry Debtors | 17,230 | |
Uninvested cash | 67,542 | |
Current Liabilities | ||
Creditors: amounts due | (24,185) | |
2,328,832 | ||
Capital and Reserves | ||
Share Capital | 23 | |
Share Premium | 1,890,142 | |
Reserves | 438,667 | |
2,328,832 | ||
Shares in Issue | 23,195,558 | |
Net Asset Value per share | 10.04 pence |
Â
Â
Portfolio Details
Â
Investments as at 30 September 2015 | Value | % of Total Portfolio | |
Magna Biopharma Income Fund | £1,139,581 | 50.2% | |
Plethora Solutions Holdings | £213,148 | 9.4% | |
Summit Corporation | £417,264 | 18.4% | |
Other quoted holdings | £254,920 | 11.2% | |
Other unquoted holdings | £243,332 | 10.8% | |
Total | £2,268,245 | 100.0% | |
Â
For further information, please contact:
Â
Port Erin Biopharma Investments Limited | Beaumont Cornish Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke (+44) (0) 1624 639396 | Roland Cornish (+44) (0) 207 628 3396 | Lucy Williams (+44) (0) 207 469 0936 |
Â